neuraxon

Mentioned in	?		References in periodicals archive	?		Medical browser	?		Full browser	?
No references found	Regis Hotel in New York This presentation will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in Phase 2 development for the treatment of acute migraine. NeurAxon, Inc. to Present at Upcoming Investor and Business ... by Business Wire These presentations will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in Phase 2 development for the treatment of acute migraine. NeurAxon, Inc. to Present at Upcoming Investor and Business ... by Business Wire US Healthcare Reform: The International Impact on Innovation and the Business of Biotech Gary Reedy of Johnson & Johnson moderates a panel that includes Brian Atwood of Versant Ventures, Ted Buckley of BIO, Steve Holtzman of Infinity Pharmaceuticals and John Andrews of NeurAxon Inc and which will address issues such as product pricing and re-imbursement in the US market and how innovation and value can be affected by future legislation. BIO-Europe 2009 Announces Program Highlights by Business Wire	neural impulse neural plate neural prosthesis neural spine neural tube neural tube defect Neural tube defects neural tube formation neuralgia neuralgia facialis vera neuralgic amyotrophy Neurally mediated hypotension neuraminic acid neuraminidase neuraminidase inhibitor neuraminidase spikes neuranagenesis neurapophysis neurapraxia neurarthropathy neurasthenia neuratrophia neuratrophic neuraxial edema neuraxis neuraxon neuraxonal dystrophy neurectasia neurectasis neurectoderm neurectomy neurectopia neurenteric neurenteric canal neurepithelium neurergic neuresthenia neurexeresis neurilemma neurilemma cell neurilemmitis neurilemmoma neurilemoma neurimotor neurinoma neurite neuritic plaque neuritis neuro check neuro- Neuro-Linguistic Programming	neurapophysis neurapophysis neurapophysis neurapraxia neurapraxia neurarthropathy neurarthropathy neurasthenia neurasthenia neurasthenia neurasthenic neurasthenic neurasthenic neurasthenic neurosis neurasthenically neurasthenically neurasthenically neurasthenics neurasthenics neurasthenics Neurath, Constantin Von Neurath, Constantin, Baron von Neurath, Konstantin, baron von Neurath, Otto Neuration neuratrophia neuratrophic neuraxial edema neuraxis neuraxis neuraxon neuraxonal dystrophy Neurbotics Neurbotics Neurbotics neurectasia neurectasis neurectoderm neurectomies neurectomies neurectomies neurectomy neurectomy neurectomy neurectopia neurelitism Neuremburg Neuremburg Neurenteric Neurenteric neurenteric canal neurenteric canal neurenteric canal neurenteric canal neurepithelium neurergic neurergic neuresthenia Neureuter Hong Kong Ltd. neurexeresis Neuridin

Mentioned in

References in periodicals archive

Medical browser

Full browser

No references found

Regis Hotel in New York This presentation will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in Phase 2 development for the treatment of acute migraine.

NeurAxon, Inc. to Present at Upcoming Investor and Business ... by Business Wire

These presentations will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in Phase 2 development for the treatment of acute migraine.

NeurAxon, Inc. to Present at Upcoming Investor and Business ... by Business Wire

US Healthcare Reform: The International Impact on Innovation and the Business of Biotech Gary Reedy of Johnson & Johnson moderates a panel that includes Brian Atwood of Versant Ventures, Ted Buckley of BIO, Steve Holtzman of Infinity Pharmaceuticals and John Andrews of NeurAxon Inc and which will address issues such as product pricing and re-imbursement in the US market and how innovation and value can be affected by future legislation.

BIO-Europe 2009 Announces Program Highlights by Business Wire